AustralianSuper Pty Ltd Makes New $17.06 Million Investment in LifeStance Health Group, Inc. $LFST

AustralianSuper Pty Ltd purchased a new stake in LifeStance Health Group, Inc. (NASDAQ:LFST) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 3,101,010 shares of the company’s stock, valued at approximately $17,056,000. AustralianSuper Pty Ltd owned 0.80% of LifeStance Health Group as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in LFST. Royal Bank of Canada increased its holdings in LifeStance Health Group by 63.4% in the 1st quarter. Royal Bank of Canada now owns 70,248 shares of the company’s stock valued at $468,000 after purchasing an additional 27,244 shares during the last quarter. AQR Capital Management LLC boosted its position in shares of LifeStance Health Group by 223.0% during the first quarter. AQR Capital Management LLC now owns 51,500 shares of the company’s stock worth $343,000 after buying an additional 35,554 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of LifeStance Health Group by 3.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 142,950 shares of the company’s stock worth $952,000 after buying an additional 4,169 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of LifeStance Health Group by 1.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 615,652 shares of the company’s stock valued at $4,100,000 after buying an additional 11,331 shares in the last quarter. Finally, Corton Capital Inc. raised its holdings in shares of LifeStance Health Group by 97.7% in the 2nd quarter. Corton Capital Inc. now owns 26,655 shares of the company’s stock valued at $138,000 after buying an additional 13,171 shares during the period. 85.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at LifeStance Health Group

In other LifeStance Health Group news, Director Robert Bessler sold 119,942 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $7.04, for a total transaction of $844,391.68. Following the sale, the director owned 1,318,983 shares of the company’s stock, valued at approximately $9,285,640.32. This trade represents a 8.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ann Varanakis sold 50,000 shares of the company’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $6.90, for a total transaction of $345,000.00. Following the completion of the transaction, the insider owned 315,610 shares of the company’s stock, valued at approximately $2,177,709. The trade was a 13.68% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 270,086 shares of company stock worth $1,891,264 over the last quarter. 6.60% of the stock is currently owned by insiders.

LifeStance Health Group Price Performance

Shares of LFST opened at $7.27 on Wednesday. The firm has a market capitalization of $2.83 billion, a price-to-earnings ratio of 363.68 and a beta of 1.11. The firm’s fifty day simple moving average is $7.13 and its 200-day simple moving average is $6.24. LifeStance Health Group, Inc. has a twelve month low of $3.74 and a twelve month high of $8.30. The company has a current ratio of 1.65, a quick ratio of 1.65 and a debt-to-equity ratio of 0.17.

LifeStance Health Group (NASDAQ:LFST) last posted its earnings results on Wednesday, February 25th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.05 by ($0.02). The business had revenue of $382.20 million during the quarter, compared to analysts’ expectations of $378.51 million. LifeStance Health Group had a net margin of 0.68% and a return on equity of 0.65%. The business’s quarterly revenue was up 17.4% compared to the same quarter last year. During the same period last year, the company earned ($0.01) EPS. Equities analysts forecast that LifeStance Health Group, Inc. will post -0.18 EPS for the current fiscal year.

LifeStance Health Group announced that its board has approved a share buyback program on Wednesday, February 25th that permits the company to buyback $100.00 million in outstanding shares. This buyback authorization permits the company to reacquire up to 3.6% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. UBS Group raised their target price on LifeStance Health Group from $10.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, February 26th. BMO Capital Markets started coverage on shares of LifeStance Health Group in a report on Thursday, November 13th. They issued an “outperform” rating and a $8.00 price objective for the company. Barclays initiated coverage on shares of LifeStance Health Group in a research note on Tuesday, December 9th. They set an “overweight” rating and a $8.00 target price on the stock. Weiss Ratings raised shares of LifeStance Health Group from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday. Finally, KeyCorp upped their price objective on LifeStance Health Group from $8.00 to $9.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, LifeStance Health Group has a consensus rating of “Moderate Buy” and a consensus price target of $9.67.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.